Therapies for non-alcoholic fatty liver disease: A 2022 update

The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing and lifestyle interventions to treat this disease by addressing the underlying metabolic syndrome are often limited. Many pharmacological interventions are being studied to slow or even reverse NAFLD progression. This review for hepatologists aims to provide an updated understanding of the pathogenesis of NAFLD, current recommended therapies, and the most promising treatment options that are currently under development.

[1]  T. Hassanein,et al.  Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. , 2022, Journal of hepatology.

[2]  T. Rolph,et al.  Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial , 2021, Nature Medicine.

[3]  J. Colca,et al.  Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide , 2021, The Journal of biological chemistry.

[4]  Z. Younossi,et al.  AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease (NAFLD): Expert Review. , 2020, Gastroenterology.

[5]  K. Cusi,et al.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.

[6]  H. Völzke,et al.  Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function , 2020, Gut.

[7]  F. Tacke,et al.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors , 2020, Nature Reviews Gastroenterology & Hepatology.

[8]  Francque Sven,et al.  A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study. , 2020, Contemporary clinical trials.

[9]  K. Cusi,et al.  Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. , 2020, Contemporary clinical trials.

[10]  T. Cotter,et al.  NAFLD 2020: The State of the Disease. , 2020, Gastroenterology.

[11]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[12]  C. Byrne,et al.  Complications, morbidity and mortality of nonalcoholic fatty liver disease. , 2020, Metabolism: clinical and experimental.

[13]  Manfred von der Ohe,et al.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial , 2019, The Lancet.

[14]  S. Polyzos,et al.  Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. , 2019, European journal of pharmacology.

[15]  K. Cusi,et al.  TEMPORARY REMOVAL: Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. , 2019, Journal of hepatology.

[16]  E. Schiff,et al.  CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[17]  B. Neuschwander‐Tetri,et al.  Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2019, The Lancet.

[18]  N. Stefan,et al.  Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial , 2019, Diabetes Care.

[19]  M. Gorrell.  Faculty Opinions recommendation of Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[20]  K. Cusi,et al.  Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[21]  M. Stepanova,et al.  Epidemiology of chronic liver diseases in the USA in the past three decades , 2019, Gut.

[22]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[23]  A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) , 2019, Case Medical Research.

[24]  S. Mudaliar,et al.  Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes , 2019, Diabetes, obesity & metabolism.

[25]  T. Lehtimäki,et al.  The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients , 2019, Diabetes Care.

[26]  B. Neuschwander‐Tetri,et al.  Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial , 2018, The Lancet.

[27]  Kunihiro Suzuki,et al.  Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease , 2018, Diabetes, obesity & metabolism.

[28]  R. Seeley,et al.  Targeting FXR and FGF19 to Treat Metabolic Diseases—Lessons Learned From Bariatric Surgery , 2018, Diabetes.

[29]  D. Levy,et al.  Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[30]  A. Mithal,et al.  Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial) , 2018, Diabetes Care.

[31]  C. Peixoto,et al.  Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation , 2018, Cellular and Molecular Life Sciences.

[32]  J. Trotter,et al.  NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2018, The Lancet.

[33]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[34]  M. A. Khan,et al.  Clinical epidemiology and disease burden of nonalcoholic fatty liver disease , 2017, World journal of gastroenterology.

[35]  R. Carr,et al.  Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. , 2016, Gastroenterology clinics of North America.

[36]  P. Messa,et al.  Pathophysiology of Non Alcoholic Fatty Liver Disease , 2016, International journal of molecular sciences.

[37]  A. Jacquier,et al.  Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy , 2016, Diabetes, obesity & metabolism.

[38]  Lynne Pearce,et al.  Non-alcoholic fatty liver disease. , 2016, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[39]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[40]  Alexis M. Kalergis,et al.  Innate Immunity and Inflammation in NAFLD/NASH , 2016, Digestive Diseases and Sciences.

[41]  P. Stål.  Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. , 2015, World journal of gastroenterology.

[42]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[43]  Yan Lu,et al.  Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis , 2014, Acta Pharmacologica Sinica.

[44]  R. Safadi,et al.  The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[45]  Paolo Mariani,et al.  GENFIT: software for the analysis of small-angle X-ray and neutron scattering data of macromolecules in solution , 2014, Journal of applied crystallography.

[46]  G. Ward,et al.  The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. , 2013, Journal of hepatology.

[47]  Qunyuan Zhang,et al.  The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat deposition and hepatic inflammation in the NHLBI Family Heart Study. , 2013, Atherosclerosis.

[48]  Lixin Zhu,et al.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.

[49]  Richard A. Flavell,et al.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity , 2012, Nature.

[50]  Richard A. Flavell,et al.  NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis , 2011, Cell.

[51]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[52]  Udo Hoffmann,et al.  Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits , 2011, PLoS genetics.

[53]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[54]  G. La Torre,et al.  Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease , 2009, Hepatology.

[55]  B. S. Mohammed,et al.  Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. , 2008, Gastroenterology.

[56]  Z. Goodman.  Grading and staging systems for inflammation and fibrosis in chronic liver diseases. , 2007, Journal of hepatology.

[57]  J. Machan,et al.  Nonalcoholic Fatty Liver Disease in Severely Obese Subjects , 2007, The American Journal of Gastroenterology.

[58]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[59]  S. Solga,et al.  Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. , 2003, Journal of hepatology.

[60]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[61]  L. Adams,et al.  International Journal of Molecular Sciences the Natural Course of Non-alcoholic Fatty Liver Disease , 2022 .

[62]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.